Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT)

Mauricio Tohen, Jim Mintz, Charles L. Bowden

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: Survival analysis has superseded most other analytic techniques for maintenance treatment studies over recent decades, despite providing results based solely on a single time-point predefined event. The aim of the present study was to develop the Multi-state Outcome Analysis of Treatments (MOAT), to provide more pragmatic information for clinicians and investigators in guiding maintenance treatment decisions. The present study was one of two published studies on the development of MOAT procedures, involving a one-year comparison of olanzapine versus lithium in recently manic patients. Methods: MOAT partitions total survival time into clinically distinct periods that are operationally defined by cut points on established rating scales. For bipolar disorders, the clinical states are remission, subsyndromal and syndromal mania, mixed states, and subsyndromal and syndromal depression. Results: MOAT re-analyses of the clinical trial revealed clinically important findings not identified when utilizing Kaplan-Meier survival analyses. Compared to patients treated with lithium, patients taking olanzapine experienced significantly more time in subsyndromal depression. Patients taking lithium spent significantly more time in mixed states than did patients taking olanzapine. Conclusions: MOAT provided detailed information on treatment outcomes that was not provided by Kaplan-Meier survival analysis. Its capability to identify and aggregate time in different clinical states of bipolar disorder may aid in identifying drug effects that are important in selecting and conducting maintenance treatment.

Original languageEnglish (US)
JournalBipolar Disorders
DOIs
StateAccepted/In press - 2016

Fingerprint

olanzapine
Lithium
Survival Analysis
Bipolar Disorder
Kaplan-Meier Estimate
Therapeutics
Depression
Research Personnel
Clinical Trials

Keywords

  • Bipolar disorder
  • Outcome analysis
  • Treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

@article{6c55d9c0fb354ee79e8d331ac432197a,
title = "Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT)",
abstract = "Objectives: Survival analysis has superseded most other analytic techniques for maintenance treatment studies over recent decades, despite providing results based solely on a single time-point predefined event. The aim of the present study was to develop the Multi-state Outcome Analysis of Treatments (MOAT), to provide more pragmatic information for clinicians and investigators in guiding maintenance treatment decisions. The present study was one of two published studies on the development of MOAT procedures, involving a one-year comparison of olanzapine versus lithium in recently manic patients. Methods: MOAT partitions total survival time into clinically distinct periods that are operationally defined by cut points on established rating scales. For bipolar disorders, the clinical states are remission, subsyndromal and syndromal mania, mixed states, and subsyndromal and syndromal depression. Results: MOAT re-analyses of the clinical trial revealed clinically important findings not identified when utilizing Kaplan-Meier survival analyses. Compared to patients treated with lithium, patients taking olanzapine experienced significantly more time in subsyndromal depression. Patients taking lithium spent significantly more time in mixed states than did patients taking olanzapine. Conclusions: MOAT provided detailed information on treatment outcomes that was not provided by Kaplan-Meier survival analysis. Its capability to identify and aggregate time in different clinical states of bipolar disorder may aid in identifying drug effects that are important in selecting and conducting maintenance treatment.",
keywords = "Bipolar disorder, Outcome analysis, Treatment",
author = "Mauricio Tohen and Jim Mintz and Bowden, {Charles L.}",
year = "2016",
doi = "10.1111/bdi.12383",
language = "English (US)",
journal = "Bipolar Disorders",
issn = "1398-5647",
publisher = "Blackwell Munksgaard",

}

TY - JOUR

T1 - Analysis of bipolar maintenance treatment with lithium versus olanzapine utilizing Multi-state Outcome Analysis of Treatments (MOAT)

AU - Tohen, Mauricio

AU - Mintz, Jim

AU - Bowden, Charles L.

PY - 2016

Y1 - 2016

N2 - Objectives: Survival analysis has superseded most other analytic techniques for maintenance treatment studies over recent decades, despite providing results based solely on a single time-point predefined event. The aim of the present study was to develop the Multi-state Outcome Analysis of Treatments (MOAT), to provide more pragmatic information for clinicians and investigators in guiding maintenance treatment decisions. The present study was one of two published studies on the development of MOAT procedures, involving a one-year comparison of olanzapine versus lithium in recently manic patients. Methods: MOAT partitions total survival time into clinically distinct periods that are operationally defined by cut points on established rating scales. For bipolar disorders, the clinical states are remission, subsyndromal and syndromal mania, mixed states, and subsyndromal and syndromal depression. Results: MOAT re-analyses of the clinical trial revealed clinically important findings not identified when utilizing Kaplan-Meier survival analyses. Compared to patients treated with lithium, patients taking olanzapine experienced significantly more time in subsyndromal depression. Patients taking lithium spent significantly more time in mixed states than did patients taking olanzapine. Conclusions: MOAT provided detailed information on treatment outcomes that was not provided by Kaplan-Meier survival analysis. Its capability to identify and aggregate time in different clinical states of bipolar disorder may aid in identifying drug effects that are important in selecting and conducting maintenance treatment.

AB - Objectives: Survival analysis has superseded most other analytic techniques for maintenance treatment studies over recent decades, despite providing results based solely on a single time-point predefined event. The aim of the present study was to develop the Multi-state Outcome Analysis of Treatments (MOAT), to provide more pragmatic information for clinicians and investigators in guiding maintenance treatment decisions. The present study was one of two published studies on the development of MOAT procedures, involving a one-year comparison of olanzapine versus lithium in recently manic patients. Methods: MOAT partitions total survival time into clinically distinct periods that are operationally defined by cut points on established rating scales. For bipolar disorders, the clinical states are remission, subsyndromal and syndromal mania, mixed states, and subsyndromal and syndromal depression. Results: MOAT re-analyses of the clinical trial revealed clinically important findings not identified when utilizing Kaplan-Meier survival analyses. Compared to patients treated with lithium, patients taking olanzapine experienced significantly more time in subsyndromal depression. Patients taking lithium spent significantly more time in mixed states than did patients taking olanzapine. Conclusions: MOAT provided detailed information on treatment outcomes that was not provided by Kaplan-Meier survival analysis. Its capability to identify and aggregate time in different clinical states of bipolar disorder may aid in identifying drug effects that are important in selecting and conducting maintenance treatment.

KW - Bipolar disorder

KW - Outcome analysis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84963610777&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963610777&partnerID=8YFLogxK

U2 - 10.1111/bdi.12383

DO - 10.1111/bdi.12383

M3 - Article

JO - Bipolar Disorders

JF - Bipolar Disorders

SN - 1398-5647

ER -